Which has preferable valuation & earnings, SNY or ZTS?

Sanofi has higher revenue and earnings than Zoetis. Zoetis is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sanofi $49.35B 2.25 $8.84B $1.91 24.01 Zoetis $9.47B 3.39 $2.67B $6.07 12.80

Is SNY or ZTS more profitable?

Zoetis has a net margin of 27.49% compared to Sanofi's net margin of 8.66%. Zoetis' return on equity of 74.89% beat Sanofi's return on equity. Company Net Margins Return on Equity Return on Assets Sanofi 8.66% 14.19% 7.95% Zoetis 27.49% 74.89% 18.59%

Which has higher valuation and earnings, GSK or ZTS?

GSK has higher revenue and earnings than Zoetis. Zoetis is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GSK $43.07B 2.47 $7.54B $3.20 16.41 Zoetis $9.47B 3.39 $2.67B $6.07 12.80

Is GSK or ZTS more profitable?

Zoetis has a net margin of 27.49% compared to GSK's net margin of 14.56%. Zoetis' return on equity of 74.89% beat GSK's return on equity. Company Net Margins Return on Equity Return on Assets GSK 14.56% 43.23% 11.60% Zoetis 27.49% 74.89% 18.59%

Does the media favor GSK or ZTS?

In the previous week, Zoetis had 26 more articles in the media than GSK. MarketBeat recorded 28 mentions for Zoetis and 2 mentions for GSK. Zoetis' average media sentiment score of 1.29 beat GSK's score of 0.36 indicating that Zoetis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GSK 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zoetis 21 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 5 Negative mention(s) 1 Very Negative mention(s) Positive

Do analysts recommend ZTS or TAK?

Zoetis presently has a consensus price target of $109.23, indicating a potential upside of 40.54%. Given Zoetis' stronger consensus rating and higher possible upside, equities research analysts clearly believe Zoetis is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zoetis 2 Sell rating(s) 9 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.32 Takeda Pharmaceutical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Does the media favor ZTS or TAK?

In the previous week, Zoetis had 21 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 28 mentions for Zoetis and 7 mentions for Takeda Pharmaceutical. Zoetis' average media sentiment score of 1.29 beat Takeda Pharmaceutical's score of 0.61 indicating that Zoetis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zoetis 21 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 5 Negative mention(s) 1 Very Negative mention(s) Positive Takeda Pharmaceutical 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TEVA or ZTS?

In the previous week, Zoetis had 20 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 28 mentions for Zoetis and 8 mentions for Teva Pharmaceutical Industries. Zoetis' average media sentiment score of 1.29 beat Teva Pharmaceutical Industries' score of 0.73 indicating that Zoetis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zoetis 21 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 5 Negative mention(s) 1 Very Negative mention(s) Positive

Which has higher valuation & earnings, ZTS or ONC?

Zoetis has higher revenue and earnings than BeOne Medicines. Zoetis is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zoetis $9.47B 3.39 $2.67B $6.07 12.80 BeOne Medicines $5.34B 7.69 $286.93M $5.68 65.93

Is ZTS or ONC more profitable?

Zoetis has a net margin of 27.49% compared to BeOne Medicines' net margin of 10.70%. Zoetis' return on equity of 74.89% beat BeOne Medicines' return on equity. Company Net Margins Return on Equity Return on Assets Zoetis 27.49% 74.89% 18.59% BeOne Medicines 10.70% 14.23% 7.82%

Does the media prefer ZTS or ONC?

In the previous week, Zoetis had 25 more articles in the media than BeOne Medicines. MarketBeat recorded 28 mentions for Zoetis and 3 mentions for BeOne Medicines. Zoetis' average media sentiment score of 1.29 beat BeOne Medicines' score of 0.63 indicating that Zoetis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zoetis 21 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 5 Negative mention(s) 1 Very Negative mention(s) Positive BeOne Medicines 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Zoetis (ZTS) Competitors

$77.72 +2.70 (+3.60%)

As of 08/21/2026 03:58 PM Eastern

Compare

ZTS vs. SNY, GSK, TAK, TEVA, and ONC

Should you buy Zoetis stock or one of its competitors? Zoetis's main competitors and comparable companies include Sanofi (SNY), GSK (GSK), Takeda Pharmaceutical (TAK), Teva Pharmaceutical Industries (TEVA), and BeOne Medicines (ONC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Zoetis compare to Sanofi?

Sanofi (NASDAQ:SNY) and Zoetis (NYSE:ZTS) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations.

14.0% of Sanofi shares are owned by institutional investors. Comparatively, 92.8% of Zoetis shares are owned by institutional investors. 1.0% of Sanofi shares are owned by insiders. Comparatively, 0.2% of Zoetis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Zoetis had 28 more articles in the media than Sanofi. MarketBeat recorded 28 mentions for Zoetis and 0 mentions for Sanofi. Zoetis' average media sentiment score of 1.29 beat Sanofi's score of 1.02 indicating that Zoetis is being referred to more favorably in the news media.

Company	Overall Sentiment
Sanofi	Positive
Zoetis	Positive

Sanofi has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market. Comparatively, Zoetis has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market.

Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 3.8%. Zoetis pays an annual dividend of $2.12 per share and has a dividend yield of 2.7%. Sanofi pays out 92.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Zoetis pays out 34.9% of its earnings in the form of a dividend. Zoetis has increased its dividend for 14 consecutive years.

Zoetis has a net margin of 27.49% compared to Sanofi's net margin of 8.66%. Zoetis' return on equity of 74.89% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	8.66%	14.19%	7.95%
Zoetis	27.49%	74.89%	18.59%

Sanofi currently has a consensus target price of $49.50, indicating a potential upside of 7.96%. Zoetis has a consensus target price of $109.23, indicating a potential upside of 40.54%. Given Zoetis' higher possible upside, analysts plainly believe Zoetis is more favorable than Sanofi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	1 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.40
Zoetis	2 Sell rating(s)	9 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.32

Sanofi has higher revenue and earnings than Zoetis. Zoetis is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$49.35B	2.25	$8.84B	$1.91	24.01
Zoetis	$9.47B	3.39	$2.67B	$6.07	12.80

Summary

Zoetis beats Sanofi on 13 of the 20 factors compared between the two stocks.

How does Zoetis compare to GSK?

GSK (NYSE:GSK) and Zoetis (NYSE:ZTS) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.

GSK pays an annual dividend of $1.78 per share and has a dividend yield of 3.4%. Zoetis pays an annual dividend of $2.12 per share and has a dividend yield of 2.7%. GSK pays out 55.6% of its earnings in the form of a dividend. Zoetis pays out 34.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zoetis has raised its dividend for 14 consecutive years.

GSK has higher revenue and earnings than Zoetis. Zoetis is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$43.07B	2.47	$7.54B	$3.20	16.41
Zoetis	$9.47B	3.39	$2.67B	$6.07	12.80

Zoetis has a net margin of 27.49% compared to GSK's net margin of 14.56%. Zoetis' return on equity of 74.89% beat GSK's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	14.56%	43.23%	11.60%
Zoetis	27.49%	74.89%	18.59%

GSK presently has a consensus price target of $53.00, indicating a potential upside of 0.91%. Zoetis has a consensus price target of $109.23, indicating a potential upside of 40.54%. Given Zoetis' stronger consensus rating and higher probable upside, analysts plainly believe Zoetis is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	2 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.10
Zoetis	2 Sell rating(s)	9 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.32

GSK has a beta of 0.36, meaning that its stock price is 64% less volatile than the broader market. Comparatively, Zoetis has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market.

15.7% of GSK shares are held by institutional investors. Comparatively, 92.8% of Zoetis shares are held by institutional investors. 10.0% of GSK shares are held by insiders. Comparatively, 0.2% of Zoetis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Zoetis had 26 more articles in the media than GSK. MarketBeat recorded 28 mentions for Zoetis and 2 mentions for GSK. Zoetis' average media sentiment score of 1.29 beat GSK's score of 0.36 indicating that Zoetis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zoetis	21 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	5 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Zoetis beats GSK on 14 of the 20 factors compared between the two stocks.

How does Zoetis compare to Takeda Pharmaceutical?

Zoetis (NYSE:ZTS) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

Zoetis presently has a consensus price target of $109.23, indicating a potential upside of 40.54%. Given Zoetis' stronger consensus rating and higher possible upside, equities research analysts clearly believe Zoetis is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zoetis	2 Sell rating(s)	9 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.32
Takeda Pharmaceutical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Zoetis has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.08, indicating that its stock price is 108% less volatile than the broader market.

Zoetis has a net margin of 27.49% compared to Takeda Pharmaceutical's net margin of 3.80%. Zoetis' return on equity of 74.89% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zoetis	27.49%	74.89%	18.59%
Takeda Pharmaceutical	3.80%	10.95%	5.34%

92.8% of Zoetis shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 0.2% of Zoetis shares are held by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Zoetis pays an annual dividend of $2.12 per share and has a dividend yield of 2.7%. Takeda Pharmaceutical pays an annual dividend of $0.48 per share and has a dividend yield of 2.6%. Zoetis pays out 34.9% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 141.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Zoetis has raised its dividend for 14 consecutive years. Zoetis is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Zoetis has higher earnings, but lower revenue than Takeda Pharmaceutical. Zoetis is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zoetis	$9.47B	3.39	$2.67B	$6.07	12.80
Takeda Pharmaceutical	$28.32B	2.06	-$1.01B	$0.34	53.44

In the previous week, Zoetis had 21 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 28 mentions for Zoetis and 7 mentions for Takeda Pharmaceutical. Zoetis' average media sentiment score of 1.29 beat Takeda Pharmaceutical's score of 0.61 indicating that Zoetis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zoetis	21 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	5 Negative mention(s)	1 Very Negative mention(s)	Positive
Takeda Pharmaceutical	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Zoetis beats Takeda Pharmaceutical on 17 of the 19 factors compared between the two stocks.

How does Zoetis compare to Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries (NYSE:TEVA) and Zoetis (NYSE:ZTS) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, media sentiment and profitability.

In the previous week, Zoetis had 20 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 28 mentions for Zoetis and 8 mentions for Teva Pharmaceutical Industries. Zoetis' average media sentiment score of 1.29 beat Teva Pharmaceutical Industries' score of 0.73 indicating that Zoetis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teva Pharmaceutical Industries	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zoetis	21 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	5 Negative mention(s)	1 Very Negative mention(s)	Positive

54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 92.8% of Zoetis shares are held by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are held by insiders. Comparatively, 0.2% of Zoetis shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Teva Pharmaceutical Industries presently has a consensus price target of $42.22, suggesting a potential upside of 12.98%. Zoetis has a consensus price target of $109.23, suggesting a potential upside of 40.54%. Given Zoetis' higher possible upside, analysts plainly believe Zoetis is more favorable than Teva Pharmaceutical Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90
Zoetis	2 Sell rating(s)	9 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.32

Zoetis has a net margin of 27.49% compared to Teva Pharmaceutical Industries' net margin of 4.08%. Zoetis' return on equity of 74.89% beat Teva Pharmaceutical Industries' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	4.08%	32.64%	6.34%
Zoetis	27.49%	74.89%	18.59%

Zoetis has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Zoetis is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teva Pharmaceutical Industries	$17.26B	2.52	$1.41B	$0.60	62.28
Zoetis	$9.47B	3.39	$2.67B	$6.07	12.80

Teva Pharmaceutical Industries has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, Zoetis has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market.

Summary

Zoetis beats Teva Pharmaceutical Industries on 10 of the 16 factors compared between the two stocks.

How does Zoetis compare to BeOne Medicines?

Zoetis (NYSE:ZTS) and BeOne Medicines (NASDAQ:ONC) are both large-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership.

Zoetis presently has a consensus target price of $109.23, suggesting a potential upside of 40.54%. BeOne Medicines has a consensus target price of $402.14, suggesting a potential upside of 7.39%. Given Zoetis' higher probable upside, research analysts clearly believe Zoetis is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zoetis	2 Sell rating(s)	9 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.32
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.00

In the previous week, Zoetis had 25 more articles in the media than BeOne Medicines. MarketBeat recorded 28 mentions for Zoetis and 3 mentions for BeOne Medicines. Zoetis' average media sentiment score of 1.29 beat BeOne Medicines' score of 0.63 indicating that Zoetis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zoetis	21 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	5 Negative mention(s)	1 Very Negative mention(s)	Positive
BeOne Medicines	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zoetis has higher revenue and earnings than BeOne Medicines. Zoetis is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zoetis	$9.47B	3.39	$2.67B	$6.07	12.80
BeOne Medicines	$5.34B	7.69	$286.93M	$5.68	65.93

Zoetis has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market.

Zoetis has a net margin of 27.49% compared to BeOne Medicines' net margin of 10.70%. Zoetis' return on equity of 74.89% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zoetis	27.49%	74.89%	18.59%
BeOne Medicines	10.70%	14.23%	7.82%

92.8% of Zoetis shares are owned by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are owned by institutional investors. 0.2% of Zoetis shares are owned by insiders. Comparatively, 6.2% of BeOne Medicines shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Zoetis beats BeOne Medicines on 11 of the 17 factors compared between the two stocks.

Get Zoetis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZTS vs. The Competition

Export

Metric	Zoetis	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$32.12B	$12.60B	$7.38B	$24.31B
Dividend Yield	2.73%	2.61%	2.53%	3.70%
P/E Ratio	12.80	789.80	272.60	30.31
Price / Sales	3.39	759.74	623.32	20.99
Price / Cash	10.27	96.77	78.62	32.49
Price / Book	10.20	11.89	13.05	6.77
Net Income	$2.67B	$2.81B	$3.47B	$1.07B
7 Day Performance	5.54%	1.76%	2.09%	-0.65%
1 Month Performance	4.28%	3.83%	6.63%	3.38%
1 Year Performance	-50.28%	6.54%	25.01%	14.90%

Zoetis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZTS Zoetis	4.7198 of 5 stars	$77.72 +3.6%	$109.23 +40.5%	-50.3%	$32.12B	$9.47B	12.80	14,500	Positive News Analyst Forecast
SNY Sanofi	2.807 of 5 stars	$44.41 +1.6%	$49.50 +11.5%	-10.7%	$107.67B	$49.35B	23.25	74,846
GSK GSK	2.8585 of 5 stars	$50.29 +1.6%	$53.00 +5.4%	+30.8%	$100.16B	$33.20B	15.73	66,841	Dividend Cut
TAK Takeda Pharmaceutical	2.0508 of 5 stars	$17.39 -1.4%	N/A	+17.2%	$55.72B	$28.32B	51.15	47,000	Insider Trade
TEVA Teva Pharmaceutical Industries	3.5938 of 5 stars	$36.53 -0.7%	$42.22 +15.6%	+102.4%	$42.57B	$17.31B	60.88	33,950	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ZTS) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zoetis (ZTS) Competitors

ZTS vs. SNY, GSK, TAK, TEVA, and ONC

How does Zoetis compare to Sanofi?

Summary

How does Zoetis compare to GSK?

Summary

How does Zoetis compare to Takeda Pharmaceutical?

Summary

How does Zoetis compare to Teva Pharmaceutical Industries?

Summary

How does Zoetis compare to BeOne Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZTS vs. The Competition

Zoetis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zoetis (ZTS) Competitors

ZTS vs. SNY, GSK, TAK, TEVA, and ONC

How does Zoetis compare to Sanofi?

Do institutionals & insiders have more ownership in SNY or ZTS?

Does the media favor SNY or ZTS?

Which has more volatility & risk, SNY or ZTS?

Is SNY or ZTS a better dividend stock?

Is SNY or ZTS more profitable?

Do analysts rate SNY or ZTS?

Which has preferable valuation & earnings, SNY or ZTS?

Summary

How does Zoetis compare to GSK?

Is GSK or ZTS a better dividend stock?

Which has higher valuation and earnings, GSK or ZTS?

Is GSK or ZTS more profitable?

Do analysts rate GSK or ZTS?

Which has more risk and volatility, GSK or ZTS?

Do insiders & institutionals believe in GSK or ZTS?

Does the media favor GSK or ZTS?

Summary

How does Zoetis compare to Takeda Pharmaceutical?

Do analysts recommend ZTS or TAK?

Which has more risk & volatility, ZTS or TAK?

Is ZTS or TAK more profitable?

Do institutionals and insiders hold more shares of ZTS or TAK?

Is ZTS or TAK a better dividend stock?

Which has better earnings & valuation, ZTS or TAK?

Does the media favor ZTS or TAK?

Summary

How does Zoetis compare to Teva Pharmaceutical Industries?

Does the media favor TEVA or ZTS?

Do institutionals and insiders hold more shares of TEVA or ZTS?

Do analysts rate TEVA or ZTS?

Is TEVA or ZTS more profitable?

Which has higher valuation & earnings, TEVA or ZTS?

Which has more volatility & risk, TEVA or ZTS?

Summary

How does Zoetis compare to BeOne Medicines?

Do analysts rate ZTS or ONC?

Does the media prefer ZTS or ONC?

Which has higher valuation & earnings, ZTS or ONC?

Which has more volatility and risk, ZTS or ONC?

Is ZTS or ONC more profitable?

Do institutionals & insiders hold more shares of ZTS or ONC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZTS vs. The Competition

Zoetis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools